Li Guang-hu, Wu Yong, Zhang Xiong-ji, Cui Yong-sheng
Department of Thoracic Surgery, First Hospital of Jilin University, Changchun 130021, China.
Zhonghua Yi Xue Za Zhi. 2010 Aug 17;90(31):2212-4.
To compare the survival time of surgery combine with chemotherapy with non-surgery chemotherapy in SCLC.
37 SCLC post operation patients were received 4-6 cycles of chemotherapy of "etoposide + cisplatin or carboplatin". 37 SCLC patients were selected be control group, whose age, stage and site of tumor were similar to surgery combine with chemotherapy group, and received 6 cycles of chemotherapy of "etoposide + cisplatin or carboplatin". Two groups were followed up 5 year and compared with the survival time.
The 1, 3, 5 year survival rate of surgery combined with chemotherapy group were 72.97%, 35.13%, 21.62%. The 1, 3, 5 year survival rate of control group were 54.05%, 13.51%, 5.41%. The survival rate of stage I (P = 0.01) was significantly different, but stage II (P = 0.06) and stage III (P = 0.836) were no difference between the two group of SCLC.
It was found that surgery combined with chemotherapy got satisfactory effects in stage I SCLC.
比较手术联合化疗与非手术化疗治疗小细胞肺癌（SCLC）的生存时间。
37例SCLC术后患者接受4 - 6周期“依托泊苷 + 顺铂或卡铂”化疗。选取37例SCLC患者作为对照组，其年龄、肿瘤分期及部位与手术联合化疗组相似，接受6周期“依托泊苷 + 顺铂或卡铂”化疗。两组随访5年并比较生存时间。
手术联合化疗组1年、3年、5年生存率分别为72.97%、35.13%、21.62%。对照组1年、3年、5年生存率分别为54.05%、13.51%、5.41%。两组SCLC患者中，Ⅰ期生存率差异有统计学意义（P = 0.01），但Ⅱ期（P = 0.06）和Ⅲ期（P = 0.836）差异无统计学意义。
发现手术联合化疗在Ⅰ期SCLC中取得了满意疗效。
